MBX Biosciences Doses First Patient in Phase 3 oPTimize Trial of Canvuparatide
Carmel, Indiana and Burlington, Massachusetts – August 27, 2026 MBX Biosciences announced that the first patient has been dosed...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Carmel, Indiana and Burlington, Massachusetts – August 27, 2026 MBX Biosciences announced that the first patient has been dosed...
